Prostate movement imposes limits on safe dose-escalation with external beam radiation therapy. If the precise daily location of the prostate is known, dose escalation becomes more feasible. We have developed an approach to dose escalation using a combination of prostate brachytherapy followed by external beam radiation therapy in which fiducial markers are placed along with 125 I seeds during transperineal interstitial permanent prostate brachytherapy. These markers serve to verify daily prostate location during the subsequent external beam radiotherapy. Prior to implementing this approach, preliminary studies were performed to test visibility of the markers. Three different 125 I seed models, as well as gold and silver marker seeds were placed within tissue-equivalent phantoms. Images were obtained with conventional x-rays (75-85 kV) and 6 MV photons from a linear accelerator.
Introduction
A large body of evidence now supports the importance of dose escalation in the management of localized prostate cancer with radiation therapy (1-3). Increased radiation dose is associated with increased local and biochemical control which, in some studies has translated into improved disease-free survival (1). Several external beam approaches to radiation dose escalation are currently being implemented including 3-D conformal radiation therapy (3-D CRT), intensity modulated radiation therapy (IMRT), and proton therapy (4). A potential limitation of these approaches is that the prostate is a moving target which may shift in position several millimeters on a daily basis (5, 6) . Several strategies to overcome this problem have been studied including the use of daily rectal balloons (7, 8) to reduce prostate movement, and daily CT scans (5), urethral catheters (9) or transabdominal ultrasonography (6) before each treatment for prostate localization.
A combination of external beam radiation therapy with transperineal interstitial permanent brachytherapy has also been used as an approach to radiation dose escalation for prostate cancer (10) (11) (12) . Our preferred sequence for this combined modality therapy has been to implant the radioactive seeds first and administer the course of external beam radiation about 5-6 weeks later. The implanted seeds are clearly visible on conventional simulation films and could provide a target during standard x-ray simulation and treatment planning (11). However, modern conformal radiation therapy typically involves CT-based treatment planning rather than fluoroscopic simulation. Since the prostate is clearly visible on these CT scans, the implanted seeds are of little extra value in prostate targeting during treatment planning or daily therapy. On the other hand, if a few of the implanted seeds were visible on the linac port films used to check patient set-up, they could provide guidance for daily adjustments, much as the transabdominal ultrasonograpybased systems do. However, no 125 I or 103 Pd seeds are easily seen on port films with these high-energy photons.
We sought to develop a means of verifying prostate location on a regular basis during external beam radiation therapy that involved implantation of marker seeds (during 125 I prostate brachytherapy) that would be visible on standard port films. We report our investigation and initial clinical application of implanted gold marker seeds that can be identified on port films and are useful in "fine-tuning" patient position during subsequent external beam radiation therapy.
Materials and Methods
125 I seeds (Mentor, Amersham, and Imagyn models) and marker seeds (Best Industries gold and silver models) were placed in the center of a stack of 20 × 20 cm slabs of tissueequivalent materials stacked 16 cm thick. The same seeds were placed within an anthropomorphic phantom (Rando™). Images were obtained with 75-85 kV x-rays from an Odelft simulator. Images of the same seeds in the same phantoms were also obtained with 6 MV photons from a Varian 2300 linear accelerator.
Thirty patients received combined modality therapy consisting of a 120 Gy 125 I transperineal permanent brachytherapy procedure followed approximately 6 weeks later with a course of external beam radiation therapy to a dose of 45 Gy in 1.8 Gy fractions. In these patients, best industry gold fiducial markers were implanted under ultrasound guidance during the transperineal interstitial permanent prostate brachytherapy procedure (using Amersham 125 I seed model 6711). The gold seeds are somewhat smaller than the standard 125 I seeds but can be implanted with the same delivery systems (e.g., Mick Applicator™ or preloaded needles). To assure consistency in gold seed placement and to avoid interinvestigator variability, all gold marker seeds were implanted by a single investigator (JSW). In each patient, the gold marker seeds were placed at the most posterior aspect of the prostate (as seen on ultrasound). Marker seeds were also placed at the base and apex to mark the superior and inferior boundaries of the prostate. CT-based simulations and routine 6 MV therapy port films were obtained in all 30 patients.
To test for possible intraprostatic "seed migration," repeated CT scans approximately 5 weeks apart were obtained and evaluated in the first 14 patients.
Results
All 125 I seed models tested were easily visualized on simulator x-ray films of both the tissue-equivalent slabs and the anthropomorphic phantom ( Figure 1 ). However, no 125 I seed models were visible on films with 6 MV photons from the linear accelerator. In contrast, the gold seeds were clearly visible on both simulator and accelerator x-rays ( Figure  2 ). The silver seeds were clear on the simulator x-rays but not quite as visible as the gold seeds on the 6 MV x-rays.
The implanted 125 I seeds, as well as the gold seeds were clearly visible on CT and conventional x-rays in the 30 patients. As anticipated, the patient's 6 MV therapy port films did not show any of the implanted 125 I seeds. However, the gold marker seeds were visible on these standard port films. (Figure 3 ) Routine anterior/posterior and lateral port films taken during the 5 week course of external beam radiation therapy showed the gold marker seeds in slightly different positions from day to day (relative to fixed anatomical landmarks such as the pubic symphysis, obturator foramina, sacrum and pubis), suggesting prostate movement. Daily motion of the prostate (relative to "position zero", arbitrarily defined as the position noted on day #1) was thereby shown to range up to 8 mm in the anterior-posterior dimension and 8 mm in the superior-inferior dimension. Mean daily displacement was 4-5 mm in both the anterior-posterior and superior-inferior dimensions. Left-right displacement was less, averaging 2-3 mm. These figures represent absolute displacement from "position zero" meaning for example, either + 3mm or -3mm any given dimension; the net movement of the prostate from one day to the next therefore was as much as twice these figures. Prostate motion was distinguished from patient set-up error by position of the seeds relative to bony landmarks. Set-up errors would find the bony landmarks off their expected locations, whereas the gold seeds being in a different position relative to the bony landmarks reveal internal prostate motion. This positional change of the gold markers does not appear to be secondary to migration within the prostate, as the markers were seen at or near their original positions (relative to bony landmarks) in several cases after being seen in different locations on prior port films. In one patient, the posterior marker was observed to move from "position zero" on day #1 to -3 mm (in anterior-posterior dimension) on day #2, to +4 mm on day #4, and back to zero on day #5. Anatomically, we believe this is more consistent with the prostate shifting position and subsequently returning to its original location rather than the seeds shifting back and forth within the prostate, a conclusion reached by several other investigators (22, 23, (25) (26) (27) (28) (29) . This is further corroborated by the observation that the gold seeds consistently showed the same relative position within the prostate in the 14 patients in whom repeat CT scans were obtained five weeks apart. In these patients, the positions of the gold seeds relative to the prostate capsule and adjacent organs (e.g., rectum) were unchanged, suggesting a stable intraprostatic location. Finally, each of the 30 patients had a CT-based simulation for external beam radiation therapy, and in every case the observed positions of the gold marker seeds were consistent with their initial ultrasound-guided placement (e.g., base, apex, most posterior aspect of capsule), again suggesting stable intraprostatic sites.
During patient treatment, 15 MV photons were used. We used 6 MV photons for the routine port films, as they tend to provide better overall quality for the purposes of checking set-up. We also found that the gold seeds were more clearly visible with 6 MV than 15 MV port films and therefore we used 6 MV photons for imaging in this study.
Discussion
Radiation dose escalation has resulted in improvements in local control and biochemical disease-free survival for prostate cancer (1-3). External beam techniques useful in radiation dose escalation include 3-D CRT, IMRT, and proton therapy (1-4). Unfortunately, rectal and genitourinary complications are usually increased with higher total radia- tion doses and volume irradiated (13, 14) . Thus, an important goal of modern prostate radiation therapy is to improve delivery of high radiation doses to the prostate while further minimizing exposure of normal tissues. IMRT has recently been used by Zelefsky and colleagues to effectively escalate dose while simultaneously reducing toxicity (24). Impressive early biochemical control rates in intermediate-and high-risk patients was demonstrated through dose escalation with IMRT, further establishing the importance of dose in prostate cancer. All external beam approaches are limited however, by daily prostate movement, which in some studies have measured several millimeters (7, 8) . Variables such as the amount of urine in the bladder and amount of feces/ flatus in the rectum correlate with prostate movement. In addition to non-invasive measures such as treating with a full bladder and empty rectum, several more rigorous solutions have been proposed and investigated (18). These include daily rectal balloons to maintain a stable prostate location, (7, 8, 17) and daily pre-treatment verification of prostate location with CT scanning (5) and transrectal (15) or transabdominal ultrasound (6, 20) . Although these approaches have merits they can be uncomfortable to the patients (rectal balloons), impractical (daily CT scans), and expensive (ultrasonography). In addition to patient discomfort, the placement and filling of rectal balloons requires additional time and effort from the technical staff. Transabdominal ultrasound-based verification of prostate location is precise, however interpretation of ultrasound imaging is generally unfamiliar to therapists and radiation oncologists, and thus requires additional training and experience. There is also some hypothetical concern that the application of the transducer to the abdominal wall may result in some shifting of gas within the colon and rectum causing the prostate to move simply as a result of the sonographic imaging. Finally, the cost of the software and equipment needed for this approach can be considerable. CT imaging before treatment can pinpoint the prostate's location while the patient is in the CT suite but the prostate could easily move from the time of CT scan to treatment on the linear accelerator. This technique is also costly and time-consuming.
Rather than using external beam radiation techniques alone, total radiation dose can also be escalated by combining prostate brachytherapy and modest-dose external beam radiation (10-12). Typically external beam radiation therapy is administered first, with the brachytherapy implant as a "boost" after completion of external beam radiation (10, 12). We have been using the reverse sequence, implanting the radioactive seeds first and following this with a course of external beam radiation beginning 5-6 weeks later. With this sequence, the tumor receives a slightly higher daily radiation dose, as the low dose-rate radiation from the implanted seeds is added to the radiation from the daily external radiation treatments (11). Additionally, a radiobiological advantage may exist as the low dose-rate radiation from the seeds possibly sensitizes tumor cells to the subsequent high dose-rate external beam treatment (16). Results with a similar approach have been reported by Critz et al. who have reported an impressive 92% 5-year actuarial disease-free survival (11). Another advantage of performing brachytherapy first is the possibility of implanting gold marker seeds during the procedure as in our study. Zeitlin et al. (21) reported results with a similar sequence of brachytherapy followed by external beam radiotherapy but encountered relatively high toxicity. We sought a means of reducing toxicity by improving targeting of the prostate during the external beam component. Using daily port-film localization, conformality can be enhanced using the gold seeds to identify the prostate's daily location. With this simple image-guided approach, daily adjustments to the isocenter's location or to the posterior block edge can be made (if indicated) to minimize unnecessary rectal dose, while still providing full prostate dose.
We have demonstrated that such implanted gold marker seeds are visible on 6 MV radiotherapy port films and provide a cheap, simple, and practical means of guiding conformal external beam radiotherapy. Port films (and now electronic portal images) are familiar to both radiation therapists and radiation oncologists. Using fiducial markers implanted directly within the prostate at known locations (e.g., at the superior, inferior, and posterior edges of the prostate), patient set-up can be adjusted using the port films or electronic images radiation therapists are accustomed to. Our experience confirms that implanted gold marker seeds are an easily implemented, inexpensive and practical option. Additionally, we and others (22, 23, (25) (26) (27) (28) (29) have demonstrated that these marker seeds do not move within the prostate to any great extent. Poggi et al. (22) implanted 4-5 gold markers in 9 patients and made measurements with orthogonal films as in our study over a 7 week course of external beam radiation therapy. They observed 1.2 mm average motion over the course, which they considered negligible. However, because only orthogonal x-ray films were used (rather than CT), it remains possible that the observed positional changes of the markers relative to each other were due to prostate edema during the course of treatment and that the actual migration of the seeds within the gland is even smaller. Dehnad et al. (27) studied gold seed migration in 10 patients who underwent 3 CT studies and portal imaging during external beam radiotherapy. The standard deviation for inter-seed distance change was 0.5 mm, which was far below the CT accuracy of tumor delineation. Vigneault et al. (26) placed markers at the prostate apex in 11 patients and used electronic portal imaging to visualize the markers. In all cases the markers were easily identified. In 8 patients who underwent ultrasound imaging following the course of radiation therapy, the markers remained in the original location within the apex confirming intraprostatic stability. Importantly, in this study up to 16 mm of motion was detected between consecutive days, confirming the potential for significant prostate displacement from day to day. As in our study, most of the displacement was in the anterior-posterior and superior-inferior directions. Kitamura et al. (29) performed multiple CT studies to assess possible migration of implanted gold markers in the liver in 4 patients and in the prostate in 14 other patients. They concluded that the small amount of marker movement (standard deviation = 0.4 mm) could largely be attributed to uncertainty in CT measurement. In their study however, the authors assumed that organs do not change in shape and size or rotate, an assumption that does not hold for the prostate during a course of external beam radiation therapy (25). Thus, actual migration may possibly be even less than their estimates. Herman et al. (25) conducted a study in which electronic portal images were used to align gold marker positions prior to daily radiation therapy with their position on simulation films. If there was more than 5mm or 3 degrees discrepancy the treatment beam was realigned. Using these criteria, 53% of treatment fractions had to be re-aligned, with an average displacement measuring 5.6 mm. They noted that only 1.4 minutes was added to average treatment time using their localization procedure. With such organ-fixed visible markers, the margins used in conformal radiation therapy can be made even tighter around the prostate gland, providing improved conformality and greater confidence that we are in fact hitting our target accurately. Our data showing mean prostate displacements of 4-5 mm in the anterior-posterior and superiorinferior dimensions is consistent with other studies (25, 26) .
Radiation therapists and physicians can easily interpret the obtained images, and adjustments in patient position can be made based on these port films or images after identifying the location of the markers. The inspection of port films is relatively simple in comparison to learning and implementing a new and expensive technology such as ultrasography (19). Notably, this approach to prostate localization is very affordable in comparison to the cost of daily CT scanning and ultrasound systems. Additionally, every radiation therapy clinic has this technology already in place and there are no initial costs of acquiring a new system. As the films are obtained immediately prior to each treatment session, port film-based prostate localization is essentially "real time" in contrast to pre-treatment CT scanning. Additionally, there is no concern about the prostate shifting position between the CT scan and treatment, and no concern about the possibility of ultrasound transducer-induced prostate movement. With the use of electronic portal imaging (particularly using amorphous silicon (a-Si) flat panel imagers which produce portal images with superior image quality), daily inspection may become even easier, more accurate and more practical (23, 25, 26) .
While the use of implanted markers coupled with imaging systems is now commercially available for guiding external beam radiation therapy, at over a half million dollars the current acquisition costs of some such systems is prohibitive. Our simple strategy of exploiting visible markers implanted during brachytherapy (which evolved from our preferred sequence of combining brachytherapy and external beam radiotherapy) adds almost no additional cost or equipment. Clinical implementation of this new approach to image-guided conformal radiation therapy is now underway at various institutions.
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